查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193123

碘缺乏症治療市場：按劑型（片劑、其他）、分銷渠道（醫院藥房、藥店和零售藥店、在線供應商）：全球機會分析和行業預測，2021-2031 年

Iodine Deficiency Drug Market By Dosage Form (Tablets, Others), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 199 Pages | 商品交期: 2-3個工作天內

價格

碘是一種必需的微量元素，存在於甲狀腺激素甲狀腺素和三碘甲腺原氨酸中。

這些激素在調節體重、能量水平、體溫、皮膚、頭髮和指甲的生長、新陳代謝方面發揮著重要作用，並且是內分泌系統的重要組成部分。 然而，甲狀腺可能會變得不活躍，無法分泌足夠的激素，從而導致甲狀腺功能減退症。 碘缺乏的主要原因是甲狀腺功能減退症，它會導致發育和代謝問題。 甲狀腺功能減退症的不良影響可導致流產、死產、精神和身體殘疾以及聽力喪失等重大問題。

全球碘缺乏症藥物市場的增長是由碘缺乏病的增加、碘缺乏意識的提高以及各大製藥公司推出各種藥物所推動的。 此外，新興市場甲狀腺功能減退症患病率的增加是推動市場增長的關鍵因素。 此外，新生兒碘缺乏症的流行也促進了市場增長。 此外，世界衛生組織和聯合國兒童基金會正在世界各地開展提高碘缺乏症認識的活動，這推動了市場的增長。 例如，根據世界衛生組織 2022 年的計劃，將引入一項普遍的食鹽碘化計劃，以應對全球範圍內的碘缺乏症，從而加速市場增長。

然而，與碘缺乏症治療藥物相關的副作用和品牌產品的專利到期是減緩市場增長的因素。 過量攝入甲狀腺素會導致甲狀腺炎、甲狀腺功能亢進、甲狀腺乳頭狀癌、口中酸味、唾液分泌增加和胃腸道刺激等各種影響，阻礙市場增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章碘缺乏藥物市場：按配方分類

  • 概覽
    • 市場規模和預測
  • 藥片
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章碘缺乏藥物市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場份額分析：按國家/地區分類
  • 藥店、零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章碘缺乏藥物市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按劑型分類
    • 北美市場規模和預測：按分銷渠道
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按劑型分類
    • 歐洲市場規模和預測：按分銷渠道
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按劑型分類
    • 亞太市場規模和預測：按分銷渠道
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按劑型分類
    • LAMEA 市場規模和預測：按分銷渠道
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地區

第七章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第八章公司簡介

  • Abbott Laboratories
  • Abbvie Inc
  • Cipla Ltd
  • Fresenius SE and Co. KGaA
  • Glaxosmithkline plc
  • Lupin Ltd
  • Macleods Pharmaceuticals Ltd
  • Merck KGaA
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: A14921

Iodine is an essential trace element that is present in the thyroid hormones, thyroxine and triiodotyronine. These hormones play an important role in regulation of weight, energy levels, internal temperature, skin, hair, nail growth, metabolism and is an important part of the endocrine system. But in some cases thyroid gland is underactive i.e. it is unable to produce enough hormones due to which hypothyroidism occurs. The main cause of iodine deficiency disorder is hypothyroidism, which leads to development and metabolic problems. The adverse effects of hypothyroidism may lead to major problems such as abortion, still birth to mental and physical retardation and deafness.

The growth of global iodine deficiency drug market is driven by increase in iodine deficiency disorders, increase in awareness about iodine deficiency and also various drug launches by pharmaceutical key players. Moreover, the increase in prevalence of hypothyroidism cases in developing regions is a key factor which boosts the growth of market. Also, increase in prevalence of iodine deficiency cases in new born drives the growth of market. In addition, awareness programs across the globe by WHO, UNICEF for iodine deficiency will drive the market growth. For instance, according to WHO 2022, universal salt iodization program is introduced to combat iodine deficiency disorders across globe which fuels the growth of market.

However, side effects associated with iodine deficiency drugs and patent expiry of branded version are the restraints that decrease the growth of market. When thyroxine consumption is excess, various consequences can occur like thyroiditis, hyperthyroidism, and thyroid papillary cancer, brassy taste in the mouth, increased salivation, and gastrointestinal irritation which hinder the growth of market.

The global iodine deficiency drug market is segmented into dosage form, distribution channel and region wise. By dosage form, the market is categorized into tablets and others (softgel capsules, liquid formulations and injections). On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global iodine deficiency drug market are Abbott Laboratories, AbbVie Inc, Cipla Ltd, Fresenius SE & Co. KGaA (Fresenius Kabi), GlasxoSmithKline, Lupin, Macleods Pharmaceuticals, Merck KGaA, Pfizer, and Teva Pharmaceutical Industries Ltd, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the iodine deficiency drug market analysis from 2021 to 2031 to identify the prevailing iodine deficiency drug market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the iodine deficiency drug market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global iodine deficiency drug market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Dosage Form

  • Tablets
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Cipla Ltd
    • Abbott Laboratories
    • Abbvie Inc
    • Fresenius SE and Co. KGaA
    • Glaxosmithkline plc
    • Lupin Ltd
    • Merck KGaA
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Macleods Pharmaceuticals Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Tablets
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Others
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Hospital Pharmacies
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Drug stores and Retail Pharmacies
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Online Providers
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: IODINE DEFICIENCY DRUG MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Dosage Form
    • 6.2.3 North America Market size and forecast, by Distribution Channel
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by Dosage Form
      • 6.2.4.1.3 Market size and forecast, by Distribution Channel
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by Dosage Form
      • 6.2.4.2.3 Market size and forecast, by Distribution Channel
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by Dosage Form
      • 6.2.4.3.3 Market size and forecast, by Distribution Channel
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Dosage Form
    • 6.3.3 Europe Market size and forecast, by Distribution Channel
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by Dosage Form
      • 6.3.4.1.3 Market size and forecast, by Distribution Channel
      • 6.3.4.2 France
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by Dosage Form
      • 6.3.4.2.3 Market size and forecast, by Distribution Channel
      • 6.3.4.3 UK
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by Dosage Form
      • 6.3.4.3.3 Market size and forecast, by Distribution Channel
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by Dosage Form
      • 6.3.4.4.3 Market size and forecast, by Distribution Channel
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by Dosage Form
      • 6.3.4.5.3 Market size and forecast, by Distribution Channel
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by Dosage Form
      • 6.3.4.6.3 Market size and forecast, by Distribution Channel
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Dosage Form
    • 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by Dosage Form
      • 6.4.4.1.3 Market size and forecast, by Distribution Channel
      • 6.4.4.2 China
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by Dosage Form
      • 6.4.4.2.3 Market size and forecast, by Distribution Channel
      • 6.4.4.3 India
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by Dosage Form
      • 6.4.4.3.3 Market size and forecast, by Distribution Channel
      • 6.4.4.4 Australia
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by Dosage Form
      • 6.4.4.4.3 Market size and forecast, by Distribution Channel
      • 6.4.4.5 South Korea
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by Dosage Form
      • 6.4.4.5.3 Market size and forecast, by Distribution Channel
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by Dosage Form
      • 6.4.4.6.3 Market size and forecast, by Distribution Channel
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Dosage Form
    • 6.5.3 LAMEA Market size and forecast, by Distribution Channel
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by Dosage Form
      • 6.5.4.1.3 Market size and forecast, by Distribution Channel
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by Dosage Form
      • 6.5.4.2.3 Market size and forecast, by Distribution Channel
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by Dosage Form
      • 6.5.4.3.3 Market size and forecast, by Distribution Channel
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by Dosage Form
      • 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Abbott Laboratories
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Abbvie Inc
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Cipla Ltd
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Fresenius SE and Co. KGaA
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Glaxosmithkline plc
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Lupin Ltd
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Macleods Pharmaceuticals Ltd
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Merck KGaA
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Pfizer Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Teva Pharmaceutical Industries Ltd.
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. IODINE DEFICIENCY DRUG MARKET FOR TABLETS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. IODINE DEFICIENCY DRUG MARKET FOR TABLETS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. IODINE DEFICIENCY DRUG MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. IODINE DEFICIENCY DRUG MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. GLOBAL IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. IODINE DEFICIENCY DRUG MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. IODINE DEFICIENCY DRUG MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. IODINE DEFICIENCY DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. IODINE DEFICIENCY DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. IODINE DEFICIENCY DRUG MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. IODINE DEFICIENCY DRUG MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. IODINE DEFICIENCY DRUG MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. U.S. IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. CANADA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. CANADA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. MEXICO IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. MEXICO IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. EUROPE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. EUROPE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. EUROPE IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. GERMANY IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. GERMANY IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. FRANCE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. FRANCE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. UK IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. UK IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ITALY IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. ITALY IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. SPAIN IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. SPAIN IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. REST OF EUROPE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. REST OF EUROPE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. JAPAN IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. JAPAN IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. CHINA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. CHINA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. INDIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. INDIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. AUSTRALIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. AUSTRALIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. SOUTH KOREA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. SOUTH KOREA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. REST OF ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. REST OF ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. LAMEA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. LAMEA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. LAMEA IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. BRAZIL IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. BRAZIL IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. SAUDI ARABIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. SAUDI ARABIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. SOUTH AFRICA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. SOUTH AFRICA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. REST OF LAMEA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. REST OF LAMEA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 65.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 66.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 67.ABBOTT LABORATORIES: NET SALES
  • TABLE 68.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 69.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 70.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 71.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 72.ABBVIE INC: NET SALES
  • TABLE 73.ABBVIE INC: KEY STRATERGIES
  • TABLE 74.CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 75.CIPLA LTD: OPERATING SEGMENTS
  • TABLE 76.CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 77.CIPLA LTD: NET SALES
  • TABLE 78.CIPLA LTD: KEY STRATERGIES
  • TABLE 79.FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 80.FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS
  • TABLE 81.FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 82.FRESENIUS SE AND CO. KGAA: NET SALES
  • TABLE 83.FRESENIUS SE AND CO. KGAA: KEY STRATERGIES
  • TABLE 84.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 85.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 86.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 87.GLAXOSMITHKLINE PLC: NET SALES
  • TABLE 88.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 89.LUPIN LTD: COMPANY SNAPSHOT
  • TABLE 90.LUPIN LTD: OPERATING SEGMENTS
  • TABLE 91.LUPIN LTD: PRODUCT PORTFOLIO
  • TABLE 92.LUPIN LTD: NET SALES
  • TABLE 93.LUPIN LTD: KEY STRATERGIES
  • TABLE 94.MACLEODS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 95.MACLEODS PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 96.MACLEODS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 97.MACLEODS PHARMACEUTICALS LTD: NET SALES
  • TABLE 98.MACLEODS PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 99.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 100.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 101.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 102.MERCK KGAA: NET SALES
  • TABLE 103.MERCK KGAA: KEY STRATERGIES
  • TABLE 104.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 105.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 106.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 107.PFIZER INC.: NET SALES
  • TABLE 108.PFIZER INC.: KEY STRATERGIES
  • TABLE 109.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 110.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 111.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 112.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES
  • TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.IODINE DEFICIENCY DRUG MARKET SEGMENTATION
  • FIGURE 2.IODINE DEFICIENCY DRUG MARKET,2021-2031
  • FIGURE 3.IODINE DEFICIENCY DRUG MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.IODINE DEFICIENCY DRUG MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.IODINE DEFICIENCY DRUG MARKET,BY DOSAGE FORM,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TABLETS IODINE DEFICIENCY DRUG MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OTHERS IODINE DEFICIENCY DRUG MARKET,2021-2031(%)
  • FIGURE 15.IODINE DEFICIENCY DRUG MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES IODINE DEFICIENCY DRUG MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES IODINE DEFICIENCY DRUG MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS IODINE DEFICIENCY DRUG MARKET,2021-2031(%)
  • FIGURE 19.IODINE DEFICIENCY DRUG MARKET BY REGION,2021
  • FIGURE 20.U.S. IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 21.CANADA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 22.MEXICO IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 23.GERMANY IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 24.FRANCE IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 25.UK IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 26.ITALY IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 27.SPAIN IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 28.REST OF EUROPE IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 29.JAPAN IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 30.CHINA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 31.INDIA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 32.AUSTRALIA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 33.SOUTH KOREA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 35.BRAZIL IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 36.SAUDI ARABIA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 37.SOUTH AFRICA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF LAMEA IODINE DEFICIENCY DRUG MARKET,2021-2031($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43.COMPETITIVE DASHBOARD
  • FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 45.ABBOTT LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 46.ABBVIE INC.: NET SALES ($MILLION)
  • FIGURE 47.CIPLA LTD.: NET SALES ($MILLION)
  • FIGURE 48.FRESENIUS SE AND CO. KGAA.: NET SALES ($MILLION)
  • FIGURE 49.GLAXOSMITHKLINE PLC.: NET SALES ($MILLION)
  • FIGURE 50.LUPIN LTD.: NET SALES ($MILLION)
  • FIGURE 51.MACLEODS PHARMACEUTICALS LTD.: NET SALES ($MILLION)
  • FIGURE 52.MERCK KGAA.: NET SALES ($MILLION)
  • FIGURE 53.PFIZER INC..: NET SALES ($MILLION)
  • FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ($MILLION)